About Us
Science
Pipeline
- HMBD-001
- HMBD-501
News
Partnering
Patients
Contact
Join Us

Festival of Biologics 2024: The Hummingbird Abvantage™: Engineering immune responses for epitope-focused antibody discovery

by communications@hummingbirdbio.com on 17 October, 2024 in Posters, Posters - 2024, Publications & Posters

<< Back to Publications

Festival of Biologics 2024:
The Hummingbird Abvantage™: Engineering Immune Responses for Epitope-Focused Antibody Discovery

17 October, 2024

VIEW POSTER

<< Back to News

Previous Reading

WCLC 2024: A Phase Ib Study to Evaluate HMBD‑001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers, and HMBD‑001 in Combination with Cetuximab in Participants with Advanced Squamous Cell Cancers

Next Reading

Hummingbird Bioscience Announces Poster Presentation on HMBD-802, Novel Dual-Payload Antibody-Drug Conjugate, at EORTC-NCI-AACR 2024

Subscribe to our updates

*indicates required

*Email Address

*First Name

*Last Name

*Company

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website. For questions about this mailing list, please email communications@hummingbirdbio.com

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Festival of Biologics 2024: The Hummingbird Abvantage™: Engineering immune responses for epitope-focused antibody discovery

Festival of Biologics 2024: The Hummingbird Abvantage™: Engineering Immune Responses for Epitope-Focused Antibody Discovery

Leave a Reply Cancel reply

Festival of Biologics 2024:
The Hummingbird Abvantage™: Engineering Immune Responses for Epitope-Focused Antibody Discovery